Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669563 · ClinicalTrials.gov registry record · Early Phase 1
An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients
A Early Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT02669563 is a Early Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 16 participants.
The verdict
NCT02669563, a Early Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main goal of this study is to test two new radioactive drugs, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG) in human subjects with congestive heart failure. Evaluations of these imaging agents will include their uptake in heart, lungs and liver, their metabolic breakdown in blood, and their kinetics in the heart. Based on these studies, the better of the two drugs will be chosen for further studies in patients with heart disease. After the better compound is chosen, additional measures of its imaging properties, metabolism and pharmacokinetics will be done in subjects with heart failure.
Interventions
- DRUG [18F]4F-MHPG
- DRUG [18F]3F-PHPG
- DRUG [13N]ammonia
- DRUG [11C]HED
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669563
The ClinicalTrials.gov registry entry for NCT02669563 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which [18F]4F-MHPG is the first listed.
NCT02669563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669563 about?
NCT02669563 is a clinical study titled "An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients". The main goal of this study is to test two new radioactive drugs, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG) in human subjects with congestive heart failure. Evaluations of these imaging agents will include the...
What is the current status of trial NCT02669563?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2015-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02669563?
The interventions under investigation include: [18F]4F-MHPG (DRUG), [18F]3F-PHPG (DRUG), [13N]ammonia (DRUG), [11C]HED (DRUG).
Who is sponsoring clinical trial NCT02669563?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.